346690-99-1

Basic information

• Product Name: (2R)-N1,N1-Dimethyl-1,2-propanediamine
• Synonyms: (2R)-N1,N1-Dimethyl-1,2-propanediamine;(R)-N,N-Dimethyl-1,2-propanediamine;1,2-PropanediaMine, N1,N1-diMethyl-, (2R)-;(2R)-1-N,1-N-dimethylpropane-1,2-diamine
• CAS NO: 346690-99-1
• Molecular Formula: C5H14N2
• Molecular Weight: 102.17806
• Mol File: 346690-99-1.mol

Chemical Properties

• Boiling Point: 107℃
• Flash Point: 15℃
• Appearance: /
• Density: 0.834
• CAS DataBase Reference: (2R)-N1,N1-Dimethyl-1,2-propanediamine(CAS DataBase Reference)
• NIST Chemistry Reference: (2R)-N1,N1-Dimethyl-1,2-propanediamine(346690-99-1)
• EPA Substance Registry System: (2R)-N1,N1-Dimethyl-1,2-propanediamine(346690-99-1)

Safety Data

• Hazardous Substances Data: 346690-99-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2R)-N1,N1-Dimethyl-1,2-propanediamine serves as a crucial building block in the synthesis of various pharmaceuticals. Its chiral nature allows for the creation of enantiomerically pure compounds, which is essential for the development of effective and safe medications.
Used in Agrochemical Industry:
In the agrochemical sector, (2R)-N1,N1-Dimethyl-1,2-propanediamine is utilized as a key component in the production of pesticides and other agricultural chemicals. Its ability to form stable complexes with active ingredients enhances the performance and selectivity of these products.
Used in Specialty Chemicals:
(2R)-N1,N1-Dimethyl-1,2-propanediamine is employed as an intermediate in the manufacture of specialty chemicals, such as surfactants, coatings, and adhesives. Its unique properties contribute to the improved performance and functionality of these materials.
Used as a Catalyst in Chemical Reactions:
This chiral amine also functions as a catalyst in various chemical reactions, facilitating processes and enhancing yields. Its stereoselective nature makes it particularly valuable in asymmetric synthesis and other reactions where enantioselectivity is desired.
Overall, (2R)-N1,N1-Dimethyl-1,2-propanediamine is a versatile and valuable compound in the fields of chemistry and industry, with applications spanning pharmaceuticals, agrochemicals, specialty chemicals, and as a catalyst in chemical reactions.

Upstream product

• 15364-56-4 dimethylaminoacetone 
• 108-16-7 1-methyl-2-N,N-dimethylaminoethanol 
• 76600-38-9 P₁₆₈ 
• 15761-38-3 L-N-Boc-Ala 
• 124-40-3 dimethyl amine 
• 82111-44-2 leucinostatin A 
• 42718-51-4 (S)-benzyl 1-(dimethylamino)-1-oxopropan-2-ylcarbamate 
• 125218-78-2 tert-butyl (S)-[1-(dimethylamino)-1-oxopropan-2-yl]carbamate 
• 230643-51-3 (R)-2-amino-N,N-dimethylpropanamide 

Downstream Products

• 18997-71-2 (2-Dimethylamino-1-methyl-ethyl)-dithiocarbamic acid 
• 39265-07-1 N-(1-methyl-2-dimethylaminoethyl)-2,2'-dihydroxy-diphenylketoimin 
• 93697-26-8 N-((S)-2-Dimethylamino-1-methyl-ethyl)-benzamide 
• 6515-61-3 3-(4-chloro-phenethyl)-5-(2-dimethylamino-1-methyl-ethyl)-[1,3,5]thiadiazinane-2-thione 
• 6176-06-3 5-(2-dimethylamino-1-methyl-ethyl)-3-phenethyl-[1,3,5]thiadiazinane-2-thione 

Relevant articles and documents

SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS

Disclosed herein are compounds that selectively bind an expanded transcribed repeat r(G4C2)exp, prevent sequestration of RNA-binding proteins, and inhibit translation of repeat associated non-ATG (RAN) translation responsible for generation of toxic dipeptide repeats underlying diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The compounds and their pharmaceutical compositions are useful in treating a disease or condition characterized by an expanded G4C2 repeat RNA (r(G4C2)exp), such as ALS and FTD.

NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical com

NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, (I) in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or metabolic syndrome via inhibition of HDAC4.

Incorporation of basic side chains into cryptolepine scaffold: Structure-antimalarial activity relationships and mechanistic studies

The synthesis of cryptolepine derivatives containing basic side-chains at the C-11 position and their evaluations for antiplasmodial and cytotoxicity properties are reported. Propyl, butyl, and cycloalkyl diamine side chains significantly increased activity against chloroquine-resistant Plasmodium falciparum strains while reducing cytotoxicity when compared with the parent compound. Localization studies inside parasite blood stages by fluorescence microscopy showed that these derivatives accumulate inside the nucleus, indicating that the incorporation of a basic side chain is not sufficient enough to promote selective accumulation in the acidic digestive vacuole of the parasite. Most of the compounds within this series showed the ability to bind to a double-stranded DNA duplex as well to monomeric hematin, suggesting that these are possible targets associated with the observed antimalarial activity. Overall, these novel cryptolepine analogues with substantially improved antiplasmodial activity and selectivity index provide a promising starting point for development of potent and highly selective agents against drug-resistant malaria parasites.

An efficient and general synthesis of primary amines by ruthenium-catalyzed amination of secondary alcohols with ammonia

Atom efficiency and selectivity are the key features of the first homogeneously catalyzed amination of secondary alcohols with ammonia to give the corresponding primary amines (see scheme). This novel amination method relies on the commercially available catalyst [Ru3(CO)12]/ cataCXium PCy and does not require any additional source of hydrogen.

Cryptolepine analogues containing basic aminoalkyl side-chains at C-11: Synthesis, antiplasmodial activity, and cytotoxicity

A series of cryptolepine derivatives has been synthesized through the incorporation of short basic side-chains in the C-11 position of the 10H-indolo[3,2-b]quinoline scaffold. Their antiplasmodial activity was evaluated in vitro against the chloroquine resistant Plasmodium falciparum W2 strain, showing IC50 values between 22 and 184 nM, while their cytotoxicity was assessed using HUVEC cells, revealing three compounds with a selectivity ratio higher than 10. The most selective of these derivatives, 4d, with a selectivity ratio of 46, was also the least cytotoxic of the series.

Method of treating chloroquine-resistant malaria with aminoquinoline derivatives

Novel aminoquinoline derivatives of the general formula STR1 are described. Also described are methods for the treatment of malaria pathogens, particularly chloroquine-resistance malaria pathogens with compounds of formula I or the pharmaceutically acceptable salts and hydrolyzable esters thereof.

Structure of a Peptidal Antibiotic P168 produced by Paecilomyces lilacinus (Thom) Samson

The peptide antibiotic P168 contained a new amino acid, (2S,4S)-2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (6) and an amine, (S)-N1,N1-dimethylpropane-1,2-diamine (4) along with other unusual amino acids.The structure of the peptide was determined as (I) by in-beam mass spectrometry.

Structure of Leucinostatin A, New Peptide Antibiotic from Paecilomyces lilacinus A-267

A new antibiotic leucinostatin A was isolated from the culture filtrate of Paecilomyces lilacinus A-267 and its structure was elucidated by mass spectrometric and degradative methods.